To demonstrate Ang II-induced cardiac remodeling through an interaction between inflammatory chemokine (CXCL1) and its receptor (CXCR2) on macrophage activation, a previous study in mice reported that Ang II infusion-induced cardiac hypertrophy, fibrosis, and inflammation are significantly attenuated when treated with CXCL1 neutralizing antibody, CXCR2 inhibitor SB265610, or CXCR2 knockout, suggesting a causative role of CXCL1-CXCR2 axis in the pathogenesis of Ang II-induced cardiac remodeling [119]. This evidence concerns the gene CXCR2 and cardiac hypertrophy.